Placebos

• 

  Subject Areas on Research

  • 10 Years with ICH E10: Choice of Control Groups. 
  • 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). 
  • 7 questions to ask when evaluating a noninferiority trial. 
  • A 2-year follow-up of social phobia. Status after a brief medication trial. 
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. 
  • A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. 
  • A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. 
  • A cluster-randomized controlled trial to assess the effectiveness of using 15% DEET topical repellent with long-lasting insecticidal nets (LLINs) compared to a placebo lotion on malaria transmission. 
  • A comparison of placebo and no-treatment during a hypnotic clinical trial. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. 
  • A generalized estimating equation approach for modeling random length binary vector data. 
  • A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. 
  • A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. 
  • A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. 
  • A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. 
  • A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. 
  • A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. 
  • A polysomnography study of eszopiclone in elderly patients with insomnia. 
  • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. 
  • A randomized sham-controlled trial of a neurodynamic technique in the treatment of carpal tunnel syndrome. 
  • A randomized, double blind, placebo controlled clinical trial of the preoperative use of ketamine for reducing inflammation and pain after thoracic surgery. 
  • A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Ménière's disease. 
  • A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. 
  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. 
  • A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. 
  • AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. 
  • Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. 
  • Acupuncture to initiate labor (Acumoms 2): a randomized, sham-controlled clinical trial. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. 
  • Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. 
  • Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. 
  • Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. 
  • Aging and dietary modulation of elastase and interleukin-1 beta secretion. 
  • Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061]. 
  • An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. 
  • An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. 
  • Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. 
  • Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. 
  • Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. 
  • Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. 
  • Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. 
  • Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. 
  • Bupropion in the treatment of outpatients with asthma and major depressive disorder. 
  • Bupropion sustained release: a therapeutic overview. 
  • Caffeine augmentation of ECT. 
  • Caffeine impairs glucose metabolism in type 2 diabetes. 
  • Can we eliminate placebo in ALS clinical trials? 
  • Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. 
  • Cervical priming prior to first-trimester suction abortion with a single 15-methyl-prostaglandin F2 alpha vaginal suppository. 
  • Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. 
  • Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. 
  • Circulatory effects of fenfluramine in obese hypertensive patients. 
  • Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. 
  • Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Commercial features of placebo and therapeutic efficacy. 
  • Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. 
  • Comparison of nifedipine alone with propranolol alone for stable angina pectoris including hemodynamics at rest and during exercise. 
  • Comparison of postoperative pain outcomes after vertical or Pfannenstiel incision for major gynecologic surgery. 
  • Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. 
  • Conclusions inconsistent with results with amphetamines and divalproex. 
  • Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. 
  • Covariate adjustment increased power in randomized controlled trials: an example in traumatic brain injury. 
  • Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. 
  • Decreased spontaneous motor activity parallels reserpine-induced supersensitivity of catecholamine-responsive rat cerebral cortex adenylate cyclase. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Depression treatment in patients with general medical conditions: results from the CO-MED trial. 
  • Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. 
  • Design, methods, and conduct of the Optic Neuritis Treatment Trial. 
  • Developing the evidence for evidence-based practice. 
  • Development and evaluation of a portable sham transcranial magnetic stimulation system. 
  • Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. 
  • Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. 
  • Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. 
  • Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. 
  • Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. 
  • Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. 
  • Double-blind, placebo-controlled trial of potassium chloride in the treatment of mild hypertension. 
  • Drug-company sponsorship and the Declaration of Helsinki. 
  • Dysfunctional attitudes in depressed patients before and after clinical treatment and in normal control subjects. 
  • Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes. 
  • Early outcomes following low dose naltrexone enhancement of opioid detoxification. 
  • Eculizumab improves fatigue in refractory generalized myasthenia gravis. 
  • Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. 
  • Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. 
  • Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. 
  • Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. 
  • Effect of spinal manipulation on sensorimotor functions in back pain patients: study protocol for a randomised controlled trial. 
  • Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. 
  • Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. 
  • Effectiveness of blinding: sham suprapubic incisions in a randomized trial of retropubic midurethral sling in women undergoing vaginal prolapse surgery. 
  • Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. 
  • Effects of an oral growth hormone secretagogue in older adults. 
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 
  • Effects of divalproex on smoking cue reactivity and cessation outcomes among smokers achieving initial abstinence. 
  • Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. 
  • Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and nonsmokers. 
  • Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. 
  • Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. 
  • Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. 
  • Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. 
  • Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. 
  • Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 
  • Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. 
  • Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. 
  • Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. 
  • Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. 
  • Efficient trial designs to reduce placebo requirements. 
  • Eptifibatide in percutaneous coronary intervention. A review. 
  • Ethical issues in research in complementary and alternative medicine. 
  • Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. 
  • Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. 
  • Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. 
  • Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. 
  • Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. 
  • Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial. 
  • Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. 
  • Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. 
  • Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. 
  • Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. 
  • Ganglioside GM1 in acute ischemic stroke. The SASS Trial. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Gene expression profiling of cutaneous wound healing. 
  • Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. 
  • Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. 
  • High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. 
  • Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. 
  • Hypotensive effects of clonidine and chlorthalidone. Controlled clinical trial of drugs administered singly and in combination. 
  • IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. 
  • Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. 
  • Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. 
  • Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. 
  • Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. 
  • Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. 
  • Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. 
  • Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. 
  • Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Intravenous ondansetron in established postoperative emesis in children. S3A-381 Study Group. 
  • Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. 
  • Lack of relapse with tryptophan depletion following successful treatment with ECT. 
  • Laser Doppler flowmetry: a clinical test of pulpal vitality. 
  • Levetiracetam in social phobia: a placebo controlled pilot study. 
  • Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. 
  • Lovastatin increases exercise-induced skeletal muscle injury. 
  • Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. 
  • Low-dose glucocorticoids after in vitro fertilization and embryo transfer have no significant effect on pregnancy rate. 
  • Marijuana intoxication and brain activation in marijuana smokers. 
  • Medicine. Placebo-controls in short-term clinical trials of hypertension. 
  • Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia. 
  • Middle cerebral artery velocity during upright posture after marijuana smoking. 
  • Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. 
  • Model validity and risk of bias in randomised placebo-controlled trials of individualised homeopathic treatment. 
  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. 
  • Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. 
  • Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children. 
  • Naltrexone blockade of nicotine effects in cigarette smokers. 
  • National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. 
  • Naturalistic follow-up of youths treated for pediatric anxiety disorders. 
  • Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. 
  • Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • On non-inferiority margin and statistical tests in active control trials. 
  • On statistical analysis for placebo-challenging designs in clinical trials. 
  • Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. 
  • Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. 
  • Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. 
  • Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 
  • Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. 
  • Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy. 
  • Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. 
  • Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. 
  • Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. 
  • Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. 
  • Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. 
  • Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. 
  • Pharmacotherapy of impaired affect in recovering schizophrenic patients. 
  • Pharmacotherapy of social phobia. 
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. 
  • Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. 
  • Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. 
  • Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. 
  • Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. 
  • Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. 
  • Placebo non-response measure in sequential parallel comparison design studies. 
  • Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). 
  • Potential mediators of the mortality reduction with zoledronic acid after hip fracture. 
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes. 
  • Power considerations for trials of two experimental arms versus a standard active control or placebo. 
  • Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. 
  • Predicting response to amitriptyline in posttraumatic stress disorder. 
  • Predictors of treatment response in patients with posttraumatic stress disorder. 
  • Pregabalin in generalized anxiety disorder: a placebo-controlled trial. 
  • Prescribing "placebo treatments": results of national survey of US internists and rheumatologists. 
  • Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT. 
  • Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. 
  • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. 
  • Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. 
  • Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. 
  • Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis. 
  • Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. 
  • Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. 
  • Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 
  • Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 
  • Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 
  • Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. 
  • Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. 
  • Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. 
  • Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 
  • Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. 
  • Rationale and design of the STeroids to REduce Systemic inflammation after infant heart Surgery (STRESS) trial. 
  • Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. 
  • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). 
  • Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. 
  • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. 
  • Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 
  • Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. 
  • Relation of serum valproate concentration to response in mania. 
  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder. 
  • Responses to hypercarbia induced by acetazolamide in panic disorder patients. 
  • Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. 
  • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. 
  • Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. 
  • Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. 
  • Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). 
  • Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. 
  • Safety of nifedipine in angina pectoris: a meta-analysis. 
  • Safety of placebo controls in pediatric hypertension trials. 
  • Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. 
  • Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. 
  • Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. 
  • Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. 
  • Sertraline and the Cheshire cat in geriatric depression. 
  • Short-term trials and long-term effects. 
  • Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India. 
  • Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. 
  • Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. 
  • Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. 
  • Synthetic isoquinoline in acute respiratory disease. 
  • Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. 
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 
  • The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. 
  • The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. 
  • The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. 
  • The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. 
  • The SAMSON trial: using a placebo to improve medication tolerability. 
  • The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. 
  • The double-blind in danger: untoward consequences of informed consent. 
  • The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). 
  • The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status. 
  • The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. 
  • The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. 
  • The randomized placebo-phase design for clinical trials. 
  • The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth. 
  • The undertreatment of dysthymia. 
  • The use of placebos in unipolar major depression: the current status. 
  • The use of topical anesthesia during intravenous catheter insertion in adults: a comparison of pain scores using LMX-4 versus placebo. 
  • Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. 
  • Thyroid hormone in the treatment of post-transplant acute tubular necrosis (ATN). 
  • Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. 
  • Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. 
  • Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. 
  • Transcutaneous electrical nerve stimulation treatment of sickle cell pain crises. 
  • Transdermal nicotine for analgesia after radical retropubic prostatectomy. 
  • Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. 
  • Treatment of posttraumatic stress disorder with amitriptyline and placebo. 
  • Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. 
  • Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. 
  • Treatment of social phobia with benzodiazepines. 
  • Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues. 
  • Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. 
  • Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials. 
  • Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. 
  • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. 
  • Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. 
  • Which depressions respond to placebo? 
  • Zolpidem for persistent insomnia in SSRI-treated depressed patients. 
  • [A new quality of the therapy of anxiety and depression--escitalopram]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine